Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
January 30, 2024 17:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr.,...
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
January 18, 2024 18:10 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive...
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
January 09, 2024 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of...
Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will present at the...
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
December 21, 2023 08:30 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler as Chief...
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
December 20, 2023 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of the Myriad Collaborative...
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
November 20, 2023 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has delivered results to one million...
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
November 16, 2023 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY and FREMONT, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc., a leader in...
Myriad Genetics to Participate in Stephens Annual Investment Conference
November 09, 2023 07:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in the...
Myriad Genetics Announces Pricing of Upsized Offering of Common Stock
November 08, 2023 21:20 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced the...